The study evaluated the efficacy and safety of combining baricitinib, a Janus kinase inhibitor, with remdesivir in hospitalized adults with Covid-19. A double-blind, randomized, placebo-controlled trial was conducted, with 1033 patients randomly assigned to receive either baricitinib plus remdesivir or remdesivir alone. The primary outcome was the time to recovery, and the key secondary outcome was clinical status at day 15. Patients receiving baricitinib plus remdesivir had a median recovery time of 7 days compared to 8 days for those receiving remdesivir alone (rate ratio, 1.16; P=0.03). They also had a 30% higher odds of improving clinical status by day 15 (odds ratio, 1.3; 95% CI, 1.0 to 1.6). The combination treatment was associated with fewer serious adverse events and new infections. The 28-day mortality rate was 5.1% in the combination group and 7.8% in the control group (hazard ratio, 0.65; P=0.03). The study concluded that baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and improving clinical status, particularly in patients requiring high-flow oxygen or noninvasive ventilation.The study evaluated the efficacy and safety of combining baricitinib, a Janus kinase inhibitor, with remdesivir in hospitalized adults with Covid-19. A double-blind, randomized, placebo-controlled trial was conducted, with 1033 patients randomly assigned to receive either baricitinib plus remdesivir or remdesivir alone. The primary outcome was the time to recovery, and the key secondary outcome was clinical status at day 15. Patients receiving baricitinib plus remdesivir had a median recovery time of 7 days compared to 8 days for those receiving remdesivir alone (rate ratio, 1.16; P=0.03). They also had a 30% higher odds of improving clinical status by day 15 (odds ratio, 1.3; 95% CI, 1.0 to 1.6). The combination treatment was associated with fewer serious adverse events and new infections. The 28-day mortality rate was 5.1% in the combination group and 7.8% in the control group (hazard ratio, 0.65; P=0.03). The study concluded that baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and improving clinical status, particularly in patients requiring high-flow oxygen or noninvasive ventilation.